A new once daily pill has been approved for some patients with advanced pancreatic cancer after promising clinical trial results. The treatment targets RAS proteins, which play a major role in the growth of several pancreatic cancers.

The U.S. Food and Drug Administration (FDA) has approved daraxonrasib, an oral multi-selective RAS(ON) inhibitor, for adults with metastatic pancreatic adenocarcinoma who have received at least one prior systemic therapy or are not candidates for multiagent systemic therapy.

U.S. health officials have approved a groundbreaking pancreatic cancer drug that offers a new approach to treating the deadly form of cancer.

The FDA has approved daraxonrasib for previously treated metastatic pancreatic cancer. The targeted pill offers longer survival and fewer severe side effects in a disease with poor outcomes.

Pancreatic cancer patients with at least 21 natural teeth survived nearly two years longer after surgery than those with fewer teeth in a study of 339 people. Researchers suspect tooth loss may reflect decades of inflammation, frailty, nutrition, and other factors tied to the body’s overall resilience.